• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Weekly Roundup: June 29-July 3


ICYMI, this week’s edition features a warning from the FDA about potentially toxic hand sanitizers, the latest data from the phase 3 bimekizumab trial for psoriasis, gene expression profiling for skin cancer, PRP for periorbital rejuvenation, plus more.

In case you missed it, some of the articles we featured throughout the week include a new approved label for sarecycline, gene expression profiling for skin cancer, a newly approved dupilumab pre-filled pen for self-administration, the latest results from the phase 3 bimekizumab study for psoriasis, plans for the Skin of Color Update 2020 to go virtual, platelet-rich plasma (PRP) for periorbital rejuvenation, plus more.

Bimekizumab phase 3 data reflect rapid, durable response

Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.

FDA approves new label for sarecycline

Almirall announces the U.S. Food and Drug Administration has approved the updated label for their oral antibiotic sarecycline (Seysara) for treatment of acne vulgaris to help promote the appropriate use of the drug to aid in preventing antimicrobial resistance commonly warned when using antibiotics

Dupilumab pre-filled pen approved by FDA

The U.S. Food and Drug Administration has approved a single-dose 300 mg pre-filled pen version of dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in U.S. patients 12 years and older.

Gene expression profiling for skin cancer brings promise, pitfalls

Gene expression profiling (GEP) has the potential to improve melanoma prognostication, but shortcomings remain, one expert says.

The Mainstream Patient: June 30

In this week's edition, we feature articles about expired sunscreen, uses for cortisone cream, Johnson & Johnson deciding to stop selling skin lightening products overseas, a warning from the FDA about possible toxic hand sanitizers, plus more.

Nanotechnology: An opportunity to advance skin cancer treatment

In cancer immunotherapy, nanoparticles can be directed to different cells and tissues related to the immune response. This technology is currently being investigated to enhance drug delivery in skin cancer therapy with the hope of promoting more robust antitumor effects and improved clinical outcomes.

Dermoscopy serves dual role in melasma management

In patients with melasma, an in vivo imaging technique can effectively diagnose the condition as well as measure response to laser treatment, a recent study indicates.

Skin of Color Update 2020 to go virtual

SanovaWorks announces they are moving their annual Skin of Color Update 2020 to a virtual setting amid various other live event cancellations due to the COVID-19 pandemic.

PRP increasing in popularity for periorbital rejuvenation

Autologous platelet-rich plasma therapy is gaining in popularity and finding its niche alone and in combination with other skin rejuvenation procedures.

Proprietary supplements largely unnecessary

Consumers can get virtually all of today’s hottest skin, hair and nail nutrients without buying special supplements, an expert says.

FDA warns of potentially toxic hand sanitizers

The U.S. Food and Drug Administration (FDA) has issued a warning about potentially toxic hand sanitizers.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.